Literature DB >> 9121186

Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s.

D S Rigel1.   

Abstract

The incidence of melanoma is increasing at a rate faster than that for any other cancer in the United States and worldwide. Several factors show that this increase in incidence is real and not due to artifact. The rapid increase is not attributable to better overall counting of the cases of cancer (because the incidence of other cancers is decreasing). Furthermore, it is not due to changes in histologic criteria. Finally, the mortality rate from melanoma continues to increase at a time when survival rates are also increasing. This apparent paradox can be true only if the actual incidence is increasing at an even faster rate than the death rate. This dramatic increase in the incidence of melanoma highlights the need for improved methods of prevention, diagnosis, and treatment as melanoma becomes increasingly important as a public health issue.

Entities:  

Mesh:

Year:  1997        PMID: 9121186     DOI: 10.4065/72.4.367

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  10 in total

1.  Metastatic malignant melanoma presenting as malabsorption.

Authors:  C Baliellas; X Pagerols; N Curcó; M García-Font; M Forné; P Vives
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  A relative color approach to color discrimination for malignant melanoma detection in dermoscopy images.

Authors:  R Joe Stanley; William V Stoecker; Randy H Moss
Journal:  Skin Res Technol       Date:  2007-02       Impact factor: 2.365

3.  The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.

Authors:  Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

4.  Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.

Authors:  Mary M McCarthy; Kyle A DiVito; Mario Sznol; Daniela Kovacs; Ruth Halaban; Aaron J Berger; Keith T Flaherty; Robert L Camp; Rossitza Lazova; David L Rimm; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

5.  Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.

Authors:  Saadia A Aziz; Lucia B Jilaveanu; Christopher Zito; Robert L Camp; David L Rimm; Patricia Conrad; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

6.  Hypoxia/reoxygenation induction of monocyte chemoattractant protein-1 in melanoma cells: involvement of nuclear factor-kappaB, stimulatory protein-1 transcription factors and mitogen-activated protein kinase pathways.

Authors:  Manfred Kunz; Gisela Bloss; Reinhard Gillitzer; Gerd Gross; Matthias Goebeler; Ulf R Rapp; Stephan Ludwig
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

7.  Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Authors:  Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.

Authors:  Saadia A Aziz; Michael Davies; Elah Pick; Christopher Zito; Lucia Jilaveanu; Robert L Camp; David L Rimm; Yuval Kluger; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

9.  Post-embryonic nerve-associated precursors to adult pigment cells: genetic requirements and dynamics of morphogenesis and differentiation.

Authors:  Erine H Budi; Larissa B Patterson; David M Parichy
Journal:  PLoS Genet       Date:  2011-05-19       Impact factor: 5.917

10.  Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women.

Authors:  D Feskanich; W C Willett; D J Hunter; G A Colditz
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.